L
Lydia Scarfò
Researcher at Vita-Salute San Raffaele University
Publications - 182
Citations - 4482
Lydia Scarfò is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Chronic lymphocytic leukemia & Medicine. The author has an hindex of 32, co-authored 138 publications receiving 2988 citations. Previous affiliations of Lydia Scarfò include University of Ferrara.
Papers
More filters
Journal ArticleDOI
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.
Yair Herishanu,Irit Avivi,Anat Amit Aharon,Gabi Shefer,Shai Levi,Yotam Bronstein,Miguel Morales,Tomer Ziv,Yamit Shorer Arbel,Lydia Scarfò,Erel Joffe,Chava Perry,Paolo Ghia +12 more
TL;DR: In this article, the authors evaluated humoral immune responses to the BNT162b2 mRNA COVID-19 vaccine in patients with CLL and compared responses with those obtained in age-matched healthy control subjects.
Journal ArticleDOI
Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients.
Abi Vijenthira,Inna Y. Gong,Thomas Andrew Fox,Stephen Booth,Gordon Cook,Bruno Fattizzo,Fernando Martín-Moro,Jerome Razanamahery,John Riches,Jeffrey I. Zwicker,Rushad Patell,Marie-Christiane Mb Vekemans,Lydia Scarfò,Thomas Chatzikonstantinou,Halil Yildiz,Raphaël Lattenist,Ioannis Mantzaris,William A. Wood,Lisa K. Hicks,Lisa K. Hicks +19 more
TL;DR: Adult patients with hematologic malignancy and COVID-19, especially hospitalized patients, have a high risk of dying and adults aged ≥60 years have significantly higher mortality; pediatric patients appear to be relatively spared.
Journal ArticleDOI
Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Panagiotis Baliakas,Anastasia Hadzidimitriou,La. Sutton,Davide Rossi,E. Minga,Neus Villamor,Marta Larrayoz,Jana Kminkova,Andreas Agathangelidis,Zadie Davis,Eugen Tausch,Evangelia Stalika,Barbara Kantorová,Larry Mansouri,Lydia Scarfò,Diego Cortese,Veronika Navrkalová,Matthew J. J. Rose-Zerilli,Karin E. Smedby,Gunnar Juliusson,Achilles Anagnostopoulos,Antonios M. Makris,Alba Navarro,Julio Delgado,David Oscier,C. Belessi,Stephan Stilgenbauer,Paolo Ghia,Šárka Pospíšilová,Gianluca Gaidano,Elias Campo,Jonathan C. Strefford,Kostas Stamatopoulos,Richard Rosenquist +33 more
TL;DR: The clinical relevance of novel recurrent mutations in CLL is supported, highlighting the adverse impact of SF3B1 and TP53 mutations, even independent of IGHV mutational status, thus underscoring the need for urgent standardization/harmonization of the detection methods.
Journal ArticleDOI
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Lydia Scarfò,Thomas Chatzikonstantinou,Gian Matteo Rigolin,Giulia Quaresmini,Marina Motta,Candida Vitale,José A. García-Marco,Jose Angel Hernandez-Rivas,Fatima Miras,Mónica Baile,Juan Marquet,Carsten Utoft Niemann,Gianluigi Reda,Talha Munir,Eva Gimeno,Monia Marchetti,Francesca Maria Quaglia,Marzia Varettoni,Julio Delgado,Sunil Iyengar,Ann Janssens,Roberto Marasca,Angela Ferrari,Carolina Cuéllar-García,Gilad Itchaki,Martin Spacek,Lorenzo De Paoli,Luca Laurenti,Mark-David Levin,Enrico Lista,Francesca Romana Mauro,Martin Simkovic,Ellen van der Spek,Elisabeth Vandenberghe,Livio Trentin,Ewa Wasik-Szczepanek,Rosa Ruchlemer,Dominique Bron,Maria Rosaria De Paolis,Giovanni Del Poeta,Lucia Farina,Myriam Foglietta,Massimo Gentile,Yair Herishanu,Tobias Herold,Ozren Jakšić,Arnon P. Kater,Sabina Kersting,Lara Malerba,Lorella Orsucci,Viola Maria Popov,Paolo Sportoletti,Mohamed A. Yassin,Barbara Pocali,Gábor Barna,Annalisa Chiarenza,Gimena Dos Santos,Eugene Nikitin,Martin Andres,Maria Dimou,Michael Doubek,Alicia Enrico,Yervand K Hakobyan,Olga Kalashnikova,Macarena Ortiz Pareja,Maria Papaioannou,Davide Rossi,Nimish Shah,Amit Shrestha,Oana Stanca,Niki Stavroyianni,Vladimir Strugov,Constantine S. Tam,Mihnea Zdrenghea,Marta Coscia,Kostas Stamatopoulos,Giuseppe Rossi,Alessandro Rambaldi,Emili Montserrat,Robin Foà,Antonio Cuneo,Paolo Ghia +81 more
TL;DR: In CLL, COVID-19 severity increases with age; antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.
Journal ArticleDOI
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL.
Claudia Fazi,Lydia Scarfò,Lorenza Pecciarini,Francesca Cottini,Antonis Dagklis,Agnieszka Janus,Anna Talarico,Cristina Scielzo,Cinzia Sala,Daniela Toniolo,Federico Caligaris-Cappio,Paolo Ghia +11 more
TL;DR: The risk of progression into CLL for low-count population-screening CLL-like MBL is exceedingly rare and definitely lower than that of clinical MBL and chromosomal abnormalities occur early in the natural history and are possibly associated with the appearance of the typical phenotype.